There are no medications available in the U.S. for treating stress urinary incontinence. Findings from a new Cleveland Clinic study suggest a muscle growth promoter may be a pharmaceutical option.
Cleveland Clinic will be one of the participating sites for a national study designed to evaluate the safety and efficacy of using a patient’s muscle-derived stem cells in the treatment of stress urinary incontinence, the most common type of urinary incontinence in women.
Midurethral slings are the current gold standard of treatment for stress urinary incontinence. Given the recent FDA recall of transvaginal mesh in pelvic organ prolapse repair, there is concern that MUS may be next. A new study examines the effectiveness of treatment options.
FDA recall of transvaginal mesh applies to some, but not all, pelvic floor procedures, urogynecologist Dr. Marie Fidela Paraiso explains.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Surgery for stress urinary incontinence can reduce overactive bladder symptoms, but the level of improvement decreases over time and can be blunted by obesity, a recent analysis reports.
Regenerating the urinary sphincter’s functional capability may be an alternative to traditional methods to restore normal pelvic anatomy in women with stress urinary incontinence. Cleveland Clinic researchers are participating in a clinical trial evaluating autologous muscle-derived stem cells for urinary sphincter repair in SUI patients.